Evaluation of the predictive value of C-reactive protein, interleukin-6 and their derived immune-inflammatory indices in COVID-19 Egyptian patients | ||||
Microbes and Infectious Diseases | ||||
Article 3, Volume 3, Issue 1, February 2022, Page 13-23 PDF (495.98 K) | ||||
Document Type: Original Article | ||||
DOI: 10.21608/mid.2021.103331.1207 | ||||
View on SCiNiTO | ||||
Authors | ||||
Sara I. Taha 1; Aalaa K. Shata2; Eman M. El-Sehsah3; Shaimaa H. Fouad 4; Aya H. Moussa 5; Shaimaa A. Abdalgeleel 6; Nouran M. Moustafa 7; Mariam K. Youssef 1 | ||||
1Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. | ||||
2Department of Pulmonary Medicine, Faculty of Medicine, Ain Shams University, Cairo,Egypt. | ||||
3Department of Medical Microbiology and Immunology, Mansoura Faculty of Medicine, Mansoura, Egypt | ||||
4Department of Internal Medicine / Allergy and Clinical Immunology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. | ||||
5Department of Anesthesia, Intensive Care and Pain Management, Faculty of Medicine, Ain Shams University, Cairo, Egypt. | ||||
6Department of Biostatistics and Epidemiology, National Cancer Institute, Cairo University, Cairo, Egypt. | ||||
7Department of Basic Medical Science, Faculty of Medicine, Dar Al Uloom University, Riyadh, Saudi Arabia & Department of Microbiology and Immunology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. | ||||
Abstract | ||||
Background: In coronavirus disease 2019 (COVID-19), finding sensitive biomarkers is critical for detecting severe cases early and intervening effectively. Aim of the work: To compare and evaluate the value of pretreatment c-reactive protein (CRP), interleukin-6 (IL-6), and their derived immune-inflammatory indices (CRP/albumin (CRP/alb), lymphocyte/CRP (L/CRP), and lymphocyte/IL-6 (L/IL-6)) in the prediction of COVID-19 severity and in-hospital mortality. Methods: This cross-sectional study included 85 confirmed COVID-19 patients, their complete blood count with differential, as well as albumin and IL-6 levels on the day of their hospital admission, were assessed and compared. We followed all patients till their in-hospital death or discharge from the hospital. Results: On admission levels of CRP, IL-6, and CRP/alb were significantly higher (p < /em>=0.001) in severe patients and non-survivors, but L/CRP and L/IL-6 were significantly lower (p < /em>=0.001) compared to non-severe patients and non-survivors. CRP/alb and L/CRP at cut-offs of 1.65 and 260.86, respectively, were the best predictors for COVID-19 severity, while IL-6 and L/IL-6 at cut-offs of 120 pg/ml and 5.40, respectively, were the best predictors for COVID-19 in-hospital mortality. IL-6 was an independent risk factor associated with severe disease development (odds ratio (OR): 1.033; 95% confidence interval (CI): 1.002-1.066). Conclusions: Pretreatment levels of CRP, IL-6, and their derived indices should be included in the diagnostic work-up of COVID-19 to determine the severity and predict the outcome. | ||||
Keywords | ||||
COVID-19; CRP; Interleukin-6; Mortality; Severity | ||||
Statistics Article View: 616 PDF Download: 370 |
||||